Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25860627 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL11702558 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL25859959 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL25859962 | 0.78 | HPGD (0.48) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL11701411 | 0.74 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL11614216 | 0.73 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL4893352 | 0.72 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL11597819 | 0.72 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL30522589 | 0.71 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9APOLBGAA | |
| SCHEMBL29460273 | 0.71 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9APOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | YALE UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | YALE UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212202-A1 | TREATMENT OF MGMT DEFICIENT CANCER WITH 2-FLUOROETHYL-SUBSTITUTED NITROSOUREAS AND OTHER COMPOUNDS | MSH2, MGMT, MSH6 | SMN1; SMN2 103/4885NPC1 1828/4885RAB9A 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.